<DOC>
	<DOCNO>NCT02726568</DOCNO>
	<brief_summary>This trail design assess efficacy safety high dose Iconitib NSCLC patient harbor EGFR mutation brain metastasis .</brief_summary>
	<brief_title>High Dose Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases</brief_title>
	<detailed_description>The long-term control brain metastasis becomes clinical challenge . Whole brain radiotherapy , standard treatment patient multiple brain metastasis , bring modest survival improvement around 3-6 month . EGFR-TKIs like icotinib proven activity non-small cell lung cancer may provide clinical benefit brain metastases patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histological cytological confirmation nonsmall cell lung cancer ( NSCLC ) ; Diagnosis brain metastasis Gadoliniumenhanced MRI . More 3 site intracranial metastasis , long diameter intracranial lesion 3cm . Positive EGFR mutation . Life expectancy ≥3months . Have one measurable encephalic lesion accord RECIST . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L . Adequate renal function : Serum creatinine ≤1.5 x ULN , ≥ 50 ml/min . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Female subject pregnant . All human subject able comply require protocol followup procedure , able receive oral medication . Written inform consent provide . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . CSF MRI finding consistent metastasis spinal cord , meninges meningeal . Allergic Icotinib . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . Pregnancy breastfeed woman . Participate antitumor clinical trial 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>EGFR-TKI</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Icotinib</keyword>
</DOC>